Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1992-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1073/PNAS.89.23.11466PMID 1454835PMCID PMC50572
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.

  1992cited by this paper
• Therapeutic trials using tacrine and other cholinesterase inhibitors.

  1990cited by this paper
• Clinical pharmacology and the choice between theory and empiricism

  1989cited by this paper
• Pharmacokinetics of tacrine hydrochloride in Alzheimer's disease

  1989cited by this paper
• Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

  1986cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• Understanding the Dose-Effect Relationship

  1981cited by this paper

• Learning Disease Progression Models That Capture Health Disparities

  2024cites this paper
• Identification of Genetic Risk Factors Based on Disease Progression Derived From Longitudinal Brain Imaging Phenotypes

  2023cites this paper
• Strategies for developing Alzheimer’s disease treatments: application of population pharmacokinetic and pharmacodynamic models

  2022cites this paper
• Role of Disease Progression Models in Drug Development

  2022cites this paper
• Pharmacokinetic and Pharmacodynamic Modeling

  2020cites this paper
• Modelling Decline in Cognition to Decline in Function in Alzheimer's Disease.

  2020cites this paper
• Placebo effect in subjects with cognitive impairment.

  2020cites this paper
• Application of Item Response Theory to Model Disease Progression and Agomelatine Effect in Patients with Major Depressive Disorder

  2019cites this paper
• Quantifying placebo responses in clinical evaluation of neuropsychiatric symptoms in Alzheimer’s disease

  2019cites this paper
• Disease Progression Modeling: Key Concepts and Recent Developments

  2016cites this paper
• Dose‐Response Analysis of the Effect of Carbidopa‐Levodopa Extended‐Release Capsules (IPX066) in Levodopa‐Naive Patients With Parkinson Disease

  2016cites this paper
• A review of disease progression models of Parkinson's disease and applications in clinical trials

  2016cites this paper
• The future is now: Model‐based clinical trial design for Alzheimer's disease

  2015cites this paper
• Modeling the Early Identification and Intervention of Alzheimer’s Disease

  2015cites this paper
• Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials

  2015cites this paper
• Clinical pharmacology = disease progression + drug action

  2015cites this paper
• Modeling of Bounded Outcome Scores with Data on the Boundaries: Application to Disability Assessment for Dementia Scores in Alzheimer’s Disease

  2014cites this paper
• An updated Alzheimer’s disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM

  2014cites this paper
• Longitudinal conditional models with intermittent missingness: SAS code and applications

  2014cites this paper
• Alzheimer's disease progression model based on integrated biomarkers and clinical measures

  2014cites this paper
• A semi‐mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first‐in‐human single ascending dose study

  2014cites this paper
• Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics

  2014cites this paper
• Prediction of Disease Progression, Treatment Response and Dropout in Chronic Obstructive Pulmonary Disease (COPD)

  2014cites this paper
• Clinical Trial Simulation in Alzheimer’s Disease

  2014influential citation
• Qualification opinion of a novel data driven model of disease progression and trial evaluation in mild and moderate Alzheimer ’ s disease

  2013cites this paper
• Disease progression and neuroscience

  2013cites this paper
• Differential analysis of transient increases of serum cTnI in response to handling in rats

  2013cites this paper
• Comparisons of Analysis Methods for Proof-of-Concept Trials

  2013cites this paper
• Understanding Placebo Responses in Alzheimer's Disease Clinical Trials from the Literature Meta-Data and CAMD Database

  2013influential citation
• Quantification of disease progression and dropout for Alzheimer's disease.

  2013cites this paper
• Qualification opinion of a novel data driven model of disease progression and trial evaluation in mild and moderate Alzheimer's disease

  2013cites this paper
• Modeling NSCLC Progression: Recent Advances and Opportunities Available

  2013cites this paper
• An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative

  2012cites this paper
• Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database

  2012cites this paper
• Chapter 22 – Disease Progress Models

  2012cites this paper
• Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis

  2012influential citation
• Pharmacometrics: Concepts and Applications to Drug Development

  2012cites this paper
• Holford NHG and Sheiner LB “Understanding the Dose-Effect Relationship-Clinical Application of Pharmacokinetic-Pharmacodynamic Models”, Clin Pharmacokin 6:429–453 (1981)—The Backstory

  2011cites this paper
• Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients

  2011cites this paper
• Individualized dosing of calcineurin inhibitors in renal transplantation

  2011cites this paper
• Development of Clinical Trial Models and Procedures for Trial Simulations

  2011cites this paper
• Disease Progression Analysis: Towards Mechanism-Based Models

  2011cites this paper
• Interpreting the results of Parkinson's disease clinical trials: Time for a change

  2011cites this paper
• Modeling the Progression of Disease

  2011cites this paper
• Modeling glucose-insulin kinetics and development of type 2 diabetes in offspring of diabetic parents

  2011cites this paper
• Bayesian Quantitative Disease–Drug–Trial Models for Parkinson’s Disease to Guide Early Drug Development

  2011cites this paper
• Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database

  2011cites this paper
• Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders

  2011cites this paper
• Review: Efficient Rehabilitation Trial Designs Using Disease Progress Modeling: A Pediatric Traumatic Brain Injury Example

  2010cites this paper
• Quantitative Pharmacology Approach in Alzheimer’s Disease: Efficacy Modeling of Early Clinical Data to Predict Clinical Outcome of Tesofensine

  2010cites this paper
• Disease progression meta‐analysis model in Alzheimer's disease

  2010cites this paper
• Clinical Trials in the Treatment of Alzheimer's Disease Based upon Enrichment Designs

  2010cites this paper
• A meta-analytic model for Alzheimer's Disease progression incorporating both summary-level data and patient-level data

  2009cites this paper
• Efficient translational rehabilitation randomised controlled trial designs using disease progress modelling and trial simulation

  2009cites this paper
• Quantitative disease, drug, and trial models.

  2009cites this paper
• Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies

  2009cites this paper
• Bivariate or Composite Plots of Endpoints

  2009cites this paper
• Animal Models as a Tool in Systems Pharmacology Research on Parkinson's Disease

  2009cites this paper
• Mathematics for Understanding Disease

  2008cites this paper
• Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis I: Mechanistic Disease Progression Model for the Time Course of Collagen-Induced Arthritis in Lewis Rats

  2008cites this paper
• Clinical Trials Simulation: A Statistical Approach

  2008cites this paper
• A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non–Small Cell Lung Cancer Patients

  2008cites this paper
• Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.

  2007cites this paper
• Using Disease Progression Models as a Tool to Detect Drug Effect

  2007cites this paper
• Disease Progress Models

  2007cites this paper
• Introduction of Quantitative Methods in Pharmacology and Clinical Pharmacology: A Historical Overview

  2007cites this paper
• Dose Response: Pharmacokinetic–Pharmacodynamic Approach

  2006cites this paper
• Application of Clinical Trial Simulation to Compare Proof-of-Concept Study Designs for Drugs with a Slow Onset of Effect; An Example in Alzheimer's Disease

  2006influential citation
• Clinical Trials Simulation System Documentation

  2006cites this paper
• Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments

  2006cites this paper
• Pharmacokinetics and Pharmacodynamics

  2006cites this paper
• A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus

  2006cites this paper
• A pharmacokinetic/pharmacodynamic model for a platelet activating factor antagonist based on data arising from Phase I studies

  2005cites this paper
• Disease System Analysis: Basic Disease Progression Models in Degenerative Disease

  2005cites this paper
• Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling—A New Classification of Biomarkers

  2005influential citation
• How Modeling and Simulation Have Enhanced Decision Making in New Drug Development

  2005cites this paper
• The effect of tacrine and lecithin in Alzheimer's disease

  2004cites this paper
• Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis

  2003cites this paper
• Population PK/PD解析を用いた評価法

  2003cites this paper
• Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.

  2002cites this paper
• Determination of maximum effect.

  2002cites this paper
• Pharmaco-electroencephalography and pharmacokinetic/pharmacodynamic modeling in basic research: focus on human pharmacology.

  2002cites this paper
• A Brief Introduction to Monte Carlo Simulation

  2001cites this paper
• Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy

  2001cites this paper
• Evolution of Pharmacokinetics and Pharmacokinetic/Dynamic Correlations during the 20th Century

  2000cites this paper
• Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer

  2000cites this paper
• Tacrine Treatment and Nursing Home Placement: Application of the Cox Proportional Hazards Model With Time-Dependent Covariates

  1998cites this paper
• Population analysis of the pharmacokinetics and pharmacodynamics of seratrodast in patients with mild to moderate asthma

  1997cites this paper
• Role of Population Pharmacokinetics in Drug Development

  1997cites this paper
• The Use of Population Pharmacokinetics in Drug Development

  1996cites this paper
• Discovery of a novel tetrahydroacridine acetylcholinesterase inhibitor through an indexed combinatorial library.

  1995cites this paper
• Population pharmacodynamics of romazarit.

  1995cites this paper
• An application of Bayesian population pharmacokinetic/pharmacodynamic models to dose recommendation.

  1995cites this paper
• The effect of tacrine and lecithin in Alzheimer's disease. A population pharmacodynamic analysis of five clinical trials.

  1994cites this paper
• Time Course of Drug Effect

  1994cites this paper
• Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

  1992cites this paper
• The Future Is Now: Model-Based Clinical Trial Design for Alzheimer’s Disease

  year unknowncites this paper